Melanie S Joy

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis
    Melanie S Joy
    Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, USA
    Br J Clin Pharmacol 74:445-55. 2012
  2. pmc Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
    Howard Trachtman
    Cohen Children s Medical Center of New York, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA
    BMC Nephrol 12:8. 2011
  3. doi request reprint Impact of glomerular kidney diseases on the clearance of drugs
    Melanie S Joy
    Division of Nephrology and Hypertension, Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599 7155, USA
    J Clin Pharmacol 52:23S-34S. 2012
  4. ncbi request reprint Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity
    Melanie S Joy
    Division of Nephrology and Hypertension, University of North Carolina School of Medicine, UNC Kidney Center, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599 7155, USA
    Nephrol Dial Transplant 22:1963-8. 2007
  5. ncbi request reprint Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease
    Melanie S Joy
    Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7155, USA
    Pharmacotherapy 27:734-44. 2007
  6. ncbi request reprint Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment
    Melanie S Joy
    School of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, Univerisity of North Carolina, Chapel Hill, NC 27599 7155, USA
    J Manag Care Pharm 13:397-411. 2007
  7. ncbi request reprint Nephrology pharmacy: historical reflections and future challenges
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, The University of North Carolina, Chapel Hill, NC, USA
    Ann Pharmacother 41:1884-6. 2007
  8. ncbi request reprint Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, University of North Carolina Kidney Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Pharmacother 42:9-15. 2008
  9. pmc Pharmacokinetics of mycophenolic acid in patients with lupus nephritis
    Melanie S Joy
    University of North Carolina Kidney Center, Chapel Hill, North Carolina 27599 7155, USA
    Pharmacotherapy 29:7-16. 2009
  10. pmc CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, UNC Kidney Center, University of North Carolina, Chapel Hill, NC, USA
    Eur J Clin Pharmacol 65:947-53. 2009

Research Grants

Detail Information

Publications32

  1. pmc Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis
    Melanie S Joy
    Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, USA
    Br J Clin Pharmacol 74:445-55. 2012
    ..The pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide were evaluated. The influence of laboratory and pharmacogenomic covariates on pharmacokinetics was evaluated as a secondary aim...
  2. pmc Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
    Howard Trachtman
    Cohen Children s Medical Center of New York, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA
    BMC Nephrol 12:8. 2011
    ..There is a need for a flexible Phase II study design which will test such novel antifibrotic strategies in order to identify agents suitable for phase III testing...
  3. doi request reprint Impact of glomerular kidney diseases on the clearance of drugs
    Melanie S Joy
    Division of Nephrology and Hypertension, Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599 7155, USA
    J Clin Pharmacol 52:23S-34S. 2012
    ..Recommendations are provided for the design of future studies of drugs in the glomerulonephritis population and for inclusion of patients with urinary protein excretion in studies that assess drug pharmacokinetics...
  4. ncbi request reprint Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity
    Melanie S Joy
    Division of Nephrology and Hypertension, University of North Carolina School of Medicine, UNC Kidney Center, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599 7155, USA
    Nephrol Dial Transplant 22:1963-8. 2007
    ..The role of drug transporters (P-glycoprotein) and drug metabolizing enzymes (cytochrome P450) as predisposing factors toward nephrotoxicity or its prevention has not been thoroughly examined...
  5. ncbi request reprint Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease
    Melanie S Joy
    Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7155, USA
    Pharmacotherapy 27:734-44. 2007
    ....
  6. ncbi request reprint Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment
    Melanie S Joy
    School of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, Univerisity of North Carolina, Chapel Hill, NC 27599 7155, USA
    J Manag Care Pharm 13:397-411. 2007
    ..The number of patients who will be identified and prescribed therapies for complications such as secondary hyperparathyroidism (SHPT) is greater than initially proposed...
  7. ncbi request reprint Nephrology pharmacy: historical reflections and future challenges
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, The University of North Carolina, Chapel Hill, NC, USA
    Ann Pharmacother 41:1884-6. 2007
  8. ncbi request reprint Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, University of North Carolina Kidney Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Pharmacother 42:9-15. 2008
    ..The effects of statins (eg, atorvastatin) on altering nontraditional lipoprotein measures in dialysis patients have not been extensively investigated...
  9. pmc Pharmacokinetics of mycophenolic acid in patients with lupus nephritis
    Melanie S Joy
    University of North Carolina Kidney Center, Chapel Hill, North Carolina 27599 7155, USA
    Pharmacotherapy 29:7-16. 2009
    ....
  10. pmc CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, UNC Kidney Center, University of North Carolina, Chapel Hill, NC, USA
    Eur J Clin Pharmacol 65:947-53. 2009
    ..It is metabolized by cytochrome P450 (CYP) 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits...
  11. pmc Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis
    Melanie S Joy
    School of Medicine, UNC Kidney Center, University of North Carolina, Chapel Hill, NC, USA
    Eur J Clin Pharmacol 66:1119-30. 2010
    ..The role of pharmacogenomics, clinical and demographic parameters in pharmacokinetic predictions was evaluated in patients receiving mycophenolic acid (MPA)...
  12. ncbi request reprint Lanthanum carbonate
    Melanie S Joy
    School of Medicine, Division of Nephrology, University of North Carolina, Carolina Kidney Center, Chapel Hill, NC 27599 7155, USA
    Ann Pharmacother 40:234-40. 2006
    ..To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD)...
  13. ncbi request reprint Long-term glycemic control measurements in diabetic patients receiving hemodialysis
    Melanie S Joy
    Division of Nephrology and Hypertension, University of North Carolina, School of Medicine, Chapel Hill, NC 27599 7155, USA
    Am J Kidney Dis 39:297-307. 2002
    ..Thus, diabetic patients receiving hemodialysis may have long-term BG that are more properly controlled than previously determined, reducing their risks of the macro- and microvascular complications of diabetes mellitus...
  14. ncbi request reprint Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein
    Melanie S Joy
    Division of Nephrology and Hypertension, Carolina Kidney Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Pharmacotherapy 25:779-89. 2005
    ....
  15. ncbi request reprint Calcimimetics and the treatment of primary and secondary hyperparathyroidism
    Melanie S Joy
    Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Ann Pharmacother 38:1871-80. 2004
    ..To review the mechanism of action, development, and clinical application of the calcimimetic compounds being investigated for the treatment of primary and secondary hyperparathyroidism (HPT)...
  16. ncbi request reprint Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia
    Melanie S Joy
    University of North Carolina, School of Medicine, Division of Nephrology and Hypertension, Chapel Hill, NC 27599 7155, USA
    Am J Kidney Dis 42:96-107. 2003
    ....
  17. pmc Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis
    Melanie S Joy
    School of Medicine, University of North Carolina UNC at Chapel Hill, Chapel Hill, NC 27599, USA
    Ann Pharmacother 43:1020-7. 2009
    ..Mycophenolic acid (MPA) is used off-label to treat many forms of glomerulonephritis...
  18. ncbi request reprint Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis
    Kimberly A Dornbrook-Lavender
    Department of Pharmacotherapy, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
    Pharmacotherapy 25:335-44. 2005
    ..Another objective was to compare the effects of atorvastatin on lipoprotein profiles as determined by direct versus indirect assessment of lipoprotein composition...
  19. ncbi request reprint Darbepoetin alfa: a novel erythropoiesis-stimulating protein
    Melanie S Joy
    School of Medicine, Division of Nephrology and Hypertension, University of North Carolina, CB 7155, 348 MacNider Bldg, Chapel Hill, NC 27599 7155, USA Melanie_
    Ann Pharmacother 36:1183-92. 2002
    ..To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of darbepoetin alfa...
  20. ncbi request reprint Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study
    Sofia Lionaki
    UNC Kidney Center and Division of Nephrology and Hypertension, 7009 Burnett Womack, CB 7155, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 5074, USA
    Nephrol Dial Transplant 22:3508-15. 2007
    ..This association was evaluated in a southeastern US population-based case-control study...
  21. pmc Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group
    Melanie S Joy
    UNC Kidney Center and Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Am J Kidney Dis 55:50-60. 2010
    ..Antifibrotic agents, such as tumor necrosis factor alpha antagonists, are a promising strategy to slow or halt the decline in renal function, based on preclinical and clinical data...
  22. ncbi request reprint Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism
    Nora Franceschini
    University of North Carolina, School of Medicine, Division of Nephrology and Hypertension, CB 7155, 348 MacNider Building, Chapel Hill, NC 27599 7155, USA
    Expert Opin Investig Drugs 12:1413-21. 2003
    ..This drug has a favourable pharmacokinetic profile compared to its precursors and will prove useful as an additional/alternative agent in patients with primary and secondary HPT...
  23. pmc Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group
    Melanie S Joy
    University of North Carolina at Chapel Hill, University of North Carolina Kidney Center and Division of Nephrology and Hypertension, Chapel Hill, NC, USA
    Clin J Am Soc Nephrol 4:39-47. 2009
    ..The primary goal was assessment of safety, tolerability, and pharmacokinetics (PK) of rosiglitazone...
  24. ncbi request reprint A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis
    Melanie S Joy
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Nephrol Dial Transplant 20:2725-32. 2005
    ....
  25. pmc Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care
    Richard A Hansen
    University of North Carolina at Chapel Hill, School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Chapel Hill, NC 27599, USA
    Res Social Adm Pharm 5:143-53. 2009
    ..Anemia is common in chronic kidney disease (CKD), and suboptimal management of anemia can lead to serious health complications and poor quality of life (QOL)...
  26. ncbi request reprint A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis
    William F Finn
    Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7155, USA
    Curr Med Res Opin 21:657-64. 2005
    ..A 1-year extension study to two randomized controlled studies was conducted to evaluate the long-term safety of lanthanum carbonate in patients who received hemodialysis...
  27. pmc In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases
    Melanie S Joy
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina, Chapel Hill, North Carolina
    Pharmacotherapy 34:114-22. 2014
    ....
  28. doi request reprint Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis
    So Yoon Jang
    School of Medicine, Division of Nephrology and Hypertension, University of North Carolina, UNC Kidney Center, Chapel Hill, USA
    Ann Pharmacother 47:e35. 2013
    ..To report what we believe to be the first case of severe hypothyroidism with reduced drug metabolism and transport activity...
  29. ncbi request reprint Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer
    Vincent Menard
    aPharmacogenomics Laboratory, Centre Hospitalier de l Université Laval de Québec CHU de Québec Research Center and Faculty of Pharmacy bCHU de Québec Research Center and Faculty of Medicine, Laval University, Quebec, Canada cSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado dSchool of Medicine, Kidney Center, University of North Carolina, Chapel Hill, North Carolina, USA eDepartment of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden
    Pharmacogenet Genomics 23:684-96. 2013
    ..Additional exons and multiple alternative splicing events (ASEs) at the UGT2B7 locus were recently discovered...
  30. ncbi request reprint Cutaneous and systemic manifestations of drug-induced vasculitis
    Sandra M ten Holder
    Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, CB 7155, 348 MacNider Bldg, Chapel Hill, NC 27599 7155, USA
    Ann Pharmacother 36:130-47. 2002
    ..To evaluate the literature for published cases of drug-induced vasculitis with cutaneous and/or systemic manifestations...
  31. ncbi request reprint Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy
    Melanie S Joy
    Am J Kidney Dis 45:1105-18. 2005
  32. ncbi request reprint Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy
    Alan J Zillich
    Purdue Pharmacy Programs, Purdue University School of Pharmacy, Indianapolis, Indiana 46202, USA
    Pharmacotherapy 25:123-43. 2005
    ..Collectively, many opportunities exist for pharmacists who practice in the primary care setting to improve the care of patients with CKD...

Research Grants2

  1. Pharmacokinetics & Genomics in Glomerular Diseases
    MELANIE JOY; Fiscal Year: 2007
    ..The selection of collaborators with expertise in the areas of this grant will enhance the career development of Dr. Joy. ..